The Japan epigenetics market held a market value of USD 22.4 million in 2020 and is estimated to reach USD 48.6 million by the year 2027. The market is anticipated to register a CAGR of 12.8% during the forecast period.
Request To Download Sample of This Strategic Report@ https://reportocean.com/industry-verticals/sample-request?report_id=ARS204
Epigenetics is the study of how the behaviors and environment can cause variations that impact the way the person’s genes work. In contrast to genetic changes, epigenetic changes are reversible and do not change the DNA sequence of the person, but the process can change how the body reads a DNA sequence.
The rising research initiatives taken by prominent players in the epigenetics market in Japan is projected to drive the growth rate of the market. The prominent pharmaceutical companies are in favour of investing in the epigenetics area in the promising country of Japan. The rising applications of epigenetics in oncology area also boosts the market growth.
On the other hand, high costs of epigenetics instruments make it affordable for research labs in developing economies to invest in this equipment. Furthermore, the lack of skilled workforce in developing and underdeveloped countries is hampering the growth of the market.
Growing R&D expenditure in the pharmaceutical & biopharmaceutical industry
The prominent players in the market are focused on investing in research to develop innovative products and cater to services of end users and other stakeholders. For instance, in April 2021, Merck, a leading science and technology company, announced an investment of EUR 20 million to expand research and development and manufacturing capabilities at its site in Shizuoka, Japan. The investment is scheduled to be completed by January 2022. Thus, such steps drive the growth rate of the market.
Rising adoption of epigenetics for cancer treatment
Epigenetic dysregulation is generally related to human disease, especially cancer. With the growth of several drugs pointing at epigenetic regulators, epigenetic targeted mechanisms have been applied in the treatment of hematological distortions and has unveiled feasible therapeutic potential for cancers. Epigenetics therapy has been proven to be a successful method for the treatment of diverse malignancies. The rise in awareness and adoption of these mechanisms is fueling the growth of the market for epigenetics in Japan.
The Japan epigenetics market is segmented into product type, technology, application, and end user.
By Product Type
o Bisulfite Conversion Kits
o ChIP Kits
o RNA Kit
• Software Tools
o BiQ Analyzer
• Proteins & Peptides
The kits segment held the largest market share in 2020 with a market share of around 22%. This maximum share owes to the high usage of kits in epigenetics mechanisms. The ChIP kits segment is growing substantially and the market size is projected to hit USD 5 million by 2027. The services segment size will hit USD 6 million by 2025.
• DNA Methylation (Largest Market Share)
• Histone Methylation
• Histone Acetylation
• Bromodomains (Fastest Growing segment; CAGR: 14%)
• Non-coding RNA
The DNA methylation segment held the largest share owing to the high usage of this technique in the research and academic institutes. Moreover, bromodomains segment is projected to be the fastest growing segment with a CAGR of 14%.
o Cardiovascular diseases
The oncology segment is anticipated to grow at the largest share of about 55% owing to the rising applications of epigenetic in cancer treatment. The rising prevalence of cancer in Japan contributes heavily to the growth rate of this segment. Based on non-oncology, the autoimmune sub-segment is anticipated to grow at a rate of 13.2%.
By End Users
• Academic and Research Institutes
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations (CROs)
• Research and Consulting Firms
The pharmaceutical & biotechnology companies segment held the largest share owing to the tremendous usage of epigenetic mechanisms by these firms. The contract research organizations segment is expected to grow at the fastest growth rate of 13% over the forecast period.
Key players operating in the Japan epigenetics market include Epigeneron, National Institute of Genetics, Rhelixa Inc, Riken, Illumina, Inc., Daiichi Sankyo Company, Limited, Takeda Pharmaceutical Co., Abcam PLC, among others.
The prominent five players in the market hold approximately 50% of the market share. These market players are involved in strategic initiatives, such as collaborations, mergers & acquisitions, product launch, and expansions to sustain in the market. For instance, in January 2020, Illumina received product approval certification for the MiSeqDx instrument with the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. This registration permits for the distribution of the MiSeqDx as a Class I medical device in Japan and establishes Illumina K.K. as the marketing authorization holder.
Request Full Report@ https://reportocean.com/industry-verticals/sample-request?report_id=ARS204
Table Of Content
Chapter 1. Research Framework
1.1 Research Objective
1.2 Product Overview
1.3 Market Segmentation
Chapter 2. Research Methodology
2.1 Qualitative Research
2.1.1 Primary & Secondary Sources
2.2 Quantitative Research
2.2.1 Primary & Secondary Sources
2.3 Breakdown of Primary Research Respondents, By Region
2.4 Assumption for the Study
2.5 Market Size Estimation
2.6. Data Triangulation
Chapter 3. Executive Summary: Japan Epigenetics Market
Chapter 4. Japan Epigenetics Market Overview
4.1. Industry Value Chain Analysis
4.1.1. Material Provider
4.1.4. End User
4.2. Industry Outlook
4.2.1. Advances in Epigenetic Technology
4.3. PESTLE Analysis
4.4. Porter’s Five Forces Analysis
4.4.1. Bargaining Power of Suppliers
4.4.2. Bargaining Power of Buyers
4.4.3. Threat of Substitutes
4.4.4. Threat of New Entrants
4.4.5. Degree of Competition
4.5. Market Dynamics and Trends
4.5.1. Growth Drivers
4.5.4. Key Trends
4.6. Covid-19 Impact Assessment on Market Growth Trend
4.7. Market Growth and Outlook
4.7.1. Market Revenue Estimates and Forecast (US$ Mn), 2017 – 2027
4.8. Competition Dashboard
4.8.1. Market Concentration Rate
4.8.2. Company Market Share Analysis (Value %), 2020
4.8.3. Competitor Mapping
Chapter 5. Japan Epigenetics Market, By Product Type
5.1. Key Insights
5.2. Market Size and Forecast, 2017 – 2027 (US$ Mn)
220.127.116.11. Bisulfite Conversion Kits
18.104.22.168. ChIP Kits
22.214.171.124. RNA kits
5.2.4. Software Tools
126.96.36.199. BiQ Analyzer
5.2.6. Proteins & Peptides
Chapter 6. Japan Epigenetics Market, By Technology
6.1. Key Insights
6.2. Market Size and Forecast, 2017 – 2027 (US$ Mn)
6.2.1. DNA Methylation
6.2.2. Histone Methylation
6.2.3. Histone Acetylation
6.2.5. Non-Coding RNA
Chapter 7. Japan Epigenetics Market, By Application
7.1. Key Insights
7.2. Market Size and Forecast, 2017 – 2027 (US$ Mn)
188.8.131.52. Cardiovascular Diseases
Chapter 8. Japan Epigenetics Market, By End Users
8.1. Key Insights
8.2. Market Size and Forecast, 2017 – 2027 (US$ Mn)
8.2.1. Academic and Research Institutes
8.2.2. Pharmaceutical & Biotechnology Companies
8.2.3. Contract Research Organizations (CROs)
8.2.4. Research and consulting firms
Chapter 9. Company Profile (Company Overview, Financial Matrix, Sales Composition Ration, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)
9.2. National Institute of Genetics
9.3. Rhelixa Inc
9.5. Illumina, Inc.
9.6. Daiichi Sankyo Company, Limited
9.7. Takeda Pharmaceutical Co.
9.8. Abcam PLC
Place a Purchase Order For Market Study at: https://reportocean.com/industry-verticals/sample-request?report_id=ARS204
About Report Ocean:
We are the best market research reports provider in the industry. Report Ocean believes in providing quality reports to clients to meet the top line and bottom line goals which will boost your market share in today’s competitive environment. Report Ocean is a ‘one-stop solution’ for individuals, organizations, and industries that are looking for innovative market research reports.
Get in Touch with Us:
Address: 500 N Michigan Ave, Suite 600, Chicago, Illinois 60611 – UNITED STATES
Tel: +1 888 212 3539 (US – TOLL FREE)